Egfr amplification is a putative resistance mechanism for nsclc–lm patients with tki therapy and is associated with poor outcome

HIGHLIGHTS

• who: Hainan Yang from the University of Bologna, Italy have published the research work: EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome, in the Journal: (JOURNAL)
• what: This study compared 21 patients with EGFR mutations and concurrent EGFR amplification with 32 patients with EGFR mutations without concurrent EGFR amplification to assess the prognostic value of EGFR amplification in NSCLC-LM patients treated with EGFR-TKIs. To exclude the influence of TP53 mutation on the result of this study, the authors performed a multivariate . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.